Sinopharm Group Co. Ltd.
SHTDF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $56,712,586 | $58,028,367 | $54,455,185 | $44,663,152 |
| - Cash | $54,313,359 | $63,808,538 | $55,221,624 | $43,529,428 |
| + Debt | $76,386,134 | $73,781,852 | $69,590,186 | $68,368,246 |
| Enterprise Value | $78,785,361 | $68,001,681 | $68,823,747 | $69,501,970 |
| Revenue | $584,507,930 | $596,569,565 | $552,147,550 | $521,051,235 |
| % Growth | -2% | 8% | 6% | – |
| Gross Profit | $44,255,390 | $48,511,678 | $47,434,060 | $44,050,608 |
| % Margin | 7.6% | 8.1% | 8.6% | 8.5% |
| EBITDA | $20,174,941 | $26,898,972 | $26,249,164 | $24,682,055 |
| % Margin | 3.5% | 4.5% | 4.8% | 4.7% |
| Net Income | $7,049,683 | $9,053,760 | $8,525,655 | $7,758,646 |
| % Margin | 1.2% | 1.5% | 1.5% | 1.5% |
| EPS Diluted | 2.26 | 2.9 | 2.73 | 2.49 |
| % Growth | -22.1% | 6.2% | 9.6% | – |
| Operating Cash Flow | $11,546,015 | $17,173,030 | $20,963,787 | $9,308,085 |
| Capital Expenditures | -$1,968,077 | -$2,335,850 | -$2,417,529 | -$2,255,642 |
| Free Cash Flow | $9,577,938 | $14,837,180 | $18,546,258 | $7,052,443 |